Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma
Human immunodeficiency virus (HIV)-associated lymphoma poses a high mortality risk despite antiretroviral therapy (ART). Although intermediate- or high-grade B-cell lymphomas are common, anaplastic large-cell lymphomas (ALCLs) are rare and seldom affect the central nervous system (CNS). Herein, we p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2024/5534556 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559682061860864 |
|---|---|
| author | Takuya Suyama Kumiko Matsui Kosuke Makihara Masatoshi Tsuru |
| author_facet | Takuya Suyama Kumiko Matsui Kosuke Makihara Masatoshi Tsuru |
| author_sort | Takuya Suyama |
| collection | DOAJ |
| description | Human immunodeficiency virus (HIV)-associated lymphoma poses a high mortality risk despite antiretroviral therapy (ART). Although intermediate- or high-grade B-cell lymphomas are common, anaplastic large-cell lymphomas (ALCLs) are rare and seldom affect the central nervous system (CNS). Herein, we present a case of HIV-associated ALCL with isolated CNS involvement that occurred following the discontinuation of ART that was administered after treatment with brentuximab vedotin (BV)—which does not cross the blood-brain barrier. At the time of CNS recurrence, the patient’s CD4 count was 9 cells/mm3. This is the first report of CNS recurrence in HIV-associated ALCL. Considering the high risk of CNS relapse, we suggest initiating CNS prophylaxis in cases of HIV-associated ALCL, particularly in patients receiving CNS-impermeable agents such as BV. |
| format | Article |
| id | doaj-art-35571ce2a74a4129a68d6181624bd87c |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-35571ce2a74a4129a68d6181624bd87c2025-02-03T01:29:31ZengWileyCase Reports in Hematology2090-65792024-01-01202410.1155/2024/5534556Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell LymphomaTakuya Suyama0Kumiko Matsui1Kosuke Makihara2Masatoshi Tsuru3Diabetes and Hematology DivisionDiabetes and Hematology DivisionSurgical PathologyDiabetes and Hematology DivisionHuman immunodeficiency virus (HIV)-associated lymphoma poses a high mortality risk despite antiretroviral therapy (ART). Although intermediate- or high-grade B-cell lymphomas are common, anaplastic large-cell lymphomas (ALCLs) are rare and seldom affect the central nervous system (CNS). Herein, we present a case of HIV-associated ALCL with isolated CNS involvement that occurred following the discontinuation of ART that was administered after treatment with brentuximab vedotin (BV)—which does not cross the blood-brain barrier. At the time of CNS recurrence, the patient’s CD4 count was 9 cells/mm3. This is the first report of CNS recurrence in HIV-associated ALCL. Considering the high risk of CNS relapse, we suggest initiating CNS prophylaxis in cases of HIV-associated ALCL, particularly in patients receiving CNS-impermeable agents such as BV.http://dx.doi.org/10.1155/2024/5534556 |
| spellingShingle | Takuya Suyama Kumiko Matsui Kosuke Makihara Masatoshi Tsuru Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma Case Reports in Hematology |
| title | Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma |
| title_full | Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma |
| title_fullStr | Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma |
| title_full_unstemmed | Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma |
| title_short | Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma |
| title_sort | isolated central nervous system involvement after brentuximab vedotin treatment for hiv positive alk negative anaplastic large cell lymphoma |
| url | http://dx.doi.org/10.1155/2024/5534556 |
| work_keys_str_mv | AT takuyasuyama isolatedcentralnervoussysteminvolvementafterbrentuximabvedotintreatmentforhivpositivealknegativeanaplasticlargecelllymphoma AT kumikomatsui isolatedcentralnervoussysteminvolvementafterbrentuximabvedotintreatmentforhivpositivealknegativeanaplasticlargecelllymphoma AT kosukemakihara isolatedcentralnervoussysteminvolvementafterbrentuximabvedotintreatmentforhivpositivealknegativeanaplasticlargecelllymphoma AT masatoshitsuru isolatedcentralnervoussysteminvolvementafterbrentuximabvedotintreatmentforhivpositivealknegativeanaplasticlargecelllymphoma |